193 related articles for article (PubMed ID: 24667348)
1. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis.
Rossitto G; Piano S; Rosi S; Simioni P; Angeli P
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):681-4. PubMed ID: 24667348
[TBL] [Abstract][Full Text] [Related]
2. [Stenotrophomonas maltophilia and tigecycline in clinical practice].
Conde-Estévez D; Grau S; Alvarez-Lerma F
Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):170-1. PubMed ID: 22277371
[No Abstract] [Full Text] [Related]
3. Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia.
Blanquer D; De Otero J; Padilla E; Gómez F; Mayol A; Irigaray R; Espejo P; Rada MA; Makrantoni G; Pérez AR
J Chemother; 2008 Dec; 20(6):761-3. PubMed ID: 19129079
[No Abstract] [Full Text] [Related]
4. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline.
Pieringer H; Schmekal B; Biesenbach G; Pohanka E
Ann Hematol; 2010 Oct; 89(10):1063-4. PubMed ID: 20174923
[No Abstract] [Full Text] [Related]
5. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
Maseda E; Denis SE; Riquelme A; Gilsanz F
Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
[TBL] [Abstract][Full Text] [Related]
6. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.
Wu X; Zhao P; Dong L; Zhang X
Medicine (Baltimore); 2017 Dec; 96(49):e9124. PubMed ID: 29245350
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
9. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Sabanis N; Paschou E; Gavriilaki E; Kalaitzoglou A; Vasileiou S
Infect Dis (Lond); 2015; 47(10):743-6. PubMed ID: 25951751
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of superinfections during treatment with tigecycline.
Katsiari M; Ntorlis K; Nteves I; Roussou Z; Platsouka ED; Maguina A
J Chemother; 2016 Apr; 28(2):110-5. PubMed ID: 27077933
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
Giamarellou H
Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
14. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline : a critical safety review.
Kaewpoowat Q; Ostrosky-Zeichner L
Expert Opin Drug Saf; 2015 Feb; 14(2):335-42. PubMed ID: 25539800
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report.
Belvisi V; Fabietti P; Del Borgo C; Marocco R; DI Vincenzo E; Soscia F; Mastroianni CM
J Chemother; 2009 Jun; 21(3):367-8. PubMed ID: 19567363
[No Abstract] [Full Text] [Related]
17. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
